J’Onco Mentor Version 9.09 — PROSTATE PRIMARY

Desktop version. Mobile app coming.

WHAT IS J’ONCO MENTOR?LUNGBREASTHEAD & NECKPROSTATEENDOMETRIUMLIVERADRENAL GLANDKIDNEYTHYROIDBLADDERCOLON & RECTUMMELANOMA OF SKINPANCREASSTOMACHCNSHEMATOPOIETIC DISORDERSTOP CANCER SITESSTORE MANUALRADIATION GUIDESTATE REPORTABILITYICD-10-CM / SECONDARY DXODS RESOURCES

DIAGNOSIS YEAR

Select the diagnosis year first. J’Onco Mentor uses it to establish the standards cycle and to drive year-sensitive routing in this module.

SEER manual—
NAACCR cycle—
Staging context—
Standards statusSelect year
No diagnosis year selected. Year-dependent schema, staging, SSDI, grade, surgery, and manual guidance should not be assumed.

PROSTATE ANATOMY & PRIMARY SITE

PRIMARY SITE

Prostate gland

C61.9

Use C61.9 for a prostate gland primary. Transitional/urothelial carcinoma arising in the prostatic urethra is staged under the urethra schema rather than the prostate schema.

ANATOMIC LANDMARKS

Bladder · prostate · prostatic urethra · seminal vesicles · neurovascular bundles · rectum · pelvic floor · external urethral sphincter

Realistic prostate anatomy with pelvic lymph node regions and alternate views

INTERACTIVE PROSTATE BIOPSY GUIDE

Prostate biopsy regions including right and left base, mid, and apex with anatomic zones
CLINICAL T WARNING: The selected biopsy regions represent sampling locations only. Bilateral positive biopsies alone do not establish cT2c; review documented clinical findings. See the full Clinical T Staging Criteria before AJCC staging.

Click any biopsy region to mark it involved. Multiple positive cores may come from the same region, so region count is not the same as positive-core count.

BIOPSY REGIONS SELECTED
None selected.
CORE SUMMARY
Enter the positive and examined core counts.
ABSTRACTION RULE: count positive cores from the pathology report itself. Do not infer the number examined or positive from labels such as right/left lobe, base, mid, or apex.

CLINICAL T STAGING — MINIMUM EVIDENCE AND CRITERIA (PROSTATE)

Before assigning cT: Establish the documented clinical extent of the primary tumor using the applicable AJCC prostate chapter and pretreatment clinical assessment. Review the physician's clinical stage, digital rectal examination (DRE), relevant imaging, and biopsy findings. A biopsy confirms malignancy but the number or laterality of positive biopsy cores alone does not establish palpable tumor extent.

cT1: Clinically inapparent tumor that is not palpable. cT1c generally describes cancer identified by needle biopsy (for example, following an elevated PSA), when the tumor is not clinically apparent.

cT2: Tumor clinically apparent and confined within the prostate. The subcategory depends on clinically established lobe involvement: cT2a, one-half of one lobe or less; cT2b, more than one-half of one lobe but not both lobes; cT2c, both lobes.

cT3 / cT4: Documented extraprostatic extension or seminal vesicle invasion may support cT3 categories; fixation or invasion of qualifying adjacent structures may support cT4. Apply the AJCC chapter's exact definitions and evidence rules.

When evidence is insufficient: Do not infer a higher clinical T category from bilateral positive cores, a diagram selection, or PSA/Grade Group alone. Verify the physician's clinical findings and the diagnosis-year AJCC rules before assigning a category.

CLINICAL T WARNING: Selecting both right and left biopsy regions does not by itself qualify the tumor as cT2c. The diagram records biopsy locations, not the minimum clinical evidence required to determine cT2 involvement. Any suggested cT category must be reviewed against the documented clinical assessment.

BIOPSY-ASSISTED cT CALCULATOR

Selections here and on the interactive biopsy diagram stay synchronized. Click a diagram region again, or Ctrl/⌘-click here, to deselect it.
SUGGESTED CLINICAL T
cT1c
RATIONALE
Clinically inapparent tumor identified by needle biopsy is cT1c. Biopsy laterality alone does not assign cT2a/b/c.
IMPORTANT: Selecting right and left biopsy regions does not automatically make the case cT2c. The selected regions show biopsy distribution only. cT2a, cT2b, and cT2c require clinically apparent disease based on DRE or physician clinical assessment.

AJCC STAGING

Educational reference: AJCC. Confirm chapter-specific staging criteria and edition in the licensed manual.

Prostate AJCC staging schema / TNM context

Use the T, N and M controls and site-specific factors below. Verify final AJCC ID, TNM edition and stage group in the approved AJCC/SEER staging system for the diagnosis year.

AJCC

8th Edition

For 2026 prostate cases, stage grouping uses AJCC 8th Edition and incorporates T, N, M, PSA, and Grade Group.

IMPORTANT CLINICAL T NOTE

The biopsy guide provides a suggested clinical T category and may synchronize it with the staging calculator. Verify the suggested category against physician-documented clinical extent and AJCC criteria before using it for staging.

PATHOLOGIC STAGING CRITERIA — PROSTATE

Qualifying evidence: Radical prostatectomy generally provides the tissue necessary to determine pathological primary tumor extent (pT). Prostate needle biopsy alone does not establish pT. Pathologically examined pelvic regional lymph nodes can support pN.

pT / pN: Assign only categories supported by the actual pathological evidence and the site-specific AJCC rules. A diagnosis-confirming biopsy does not automatically establish a pathological primary tumor category.

pM: Pathologically proven distant metastasis may support pM1 where the chapter permits; AJCC does not use pM0.

Treatment sequence: Distinguish initial pathological classification (pTNM) from post-neoadjuvant classification (ypTNM). Confirm eligibility, histology, staging chapter and diagnosis-year edition before finalizing.

Source / verification: AJCC · SEER tools and manuals. Educational overview only; verify exact chapter-specific criteria in the licensed AJCC manual.

PROSTATE PATHOLOGIC STAGE CALCULATOR — pTNM / ypTNM

Enter only pathologically documented categories. This evidence-based worksheet displays the entered classification; it does not infer a final AJCC prognostic stage group. Confirm eligibility, treatment sequence, and stage grouping in the applicable AJCC manual.

Select the pathologic classification and supporting evidence to review the entered pTNM/ypTNM categories.
PROSTATE CLINICAL PROGNOSTIC STAGE CALCULATOR
AUTO-SYNC ENABLED: Clinical T is populated from the biopsy cT calculator. Clinical N and nodal M status are populated from the interactive lymph-node calculator. PSA and Grade Group remain required inputs for final prognostic stage grouping.

A manual value overrides the quick-select dropdown.

PSA USED
—
CLINICAL PROGNOSTIC STAGE
—
RATIONALE
Clinical T and Clinical N populate automatically from the biopsy and lymph-node calculators. Enter PSA and Grade Group to complete prognostic stage grouping.
AJCC prostate stage grouping requires PSA and Grade Group in addition to TNM. If PSA, Grade Group, or a required TNM category is unknown, the stage group may remain undetermined.

INTERACTIVE PROSTATE LYMPH NODES & CLINICAL N CALCULATOR

Realistic pelvic lymph-node anatomy for prostate cancer showing regional and nonregional nodal groups

Click any highlighted nodal group to toggle it. Regional pelvic nodes contribute to N category; nonregional nodes contribute to M1a.

NODE SELECTION
SELECTED NODES
None selected.
SUGGESTED CLINICAL N

cN0

No positive regional pelvic nodes identified.

NONREGIONAL NODE STATUS

cM0

No nonregional lymph node metastasis identified.

EOD REGIONAL NODES

000

No regional lymph node involvement.

REGIONAL (PELVIC) NODES → N1 / EOD 300
External iliac · Internal iliac / hypogastric · Obturator · Periprostatic / pelvic · Presacral / sacral
NONREGIONAL NODES → M1a (NOT N1)
Common iliac · Para-aortic / retroperitoneal
CLINICAL N CALCULATOR: Use the interactive lymph-node diagram, node dropdown, or Regional Node Assessment control. Any positive regional pelvic lymph node is cN1. Prostate has no cN2 or cN3 category. Nonregional nodal disease is staged as M1a, not as a higher N category.

ICD-O-3 HISTOLOGY

Type a code or name, or use the dropdown below. Both controls stay synchronized.
SELECTED HISTOLOGY

The 2026 SEER prostate EOD schema accepts C61.9 with broad epithelial and melanocytic histology ranges. This initial dropdown emphasizes common and registry-relevant prostate histologies; rare histologies should be verified against current ICD-O and SEER schema rules.

SEER 2027 — PROSTATE MULTIPLE PRIMARY RULES

RULE SET: Prostate uses the SEER 2026 Other Sites Multiple Primary Rules for cases diagnosed 1/1/2023 forward. Apply rules in order and stop at the first rule that applies.

INTERACTIVE PROSTATE MULTIPLE PRIMARY REVIEW

MULTIPLE PRIMARY RESULT

—

Select the pattern and calculate.

PROSTATE-SPECIFIC RULES

M3 — Acinar adenocarcinoma: Acinar adenocarcinoma of the prostate (8140) is always a single primary.

Report only one acinar/adenocarcinoma of prostate per patient lifetime. This also applies to qualifying subtype/variant forms listed with acinar adenocarcinoma.

M4 — Subsequent small cell carcinoma: Abstract multiple primaries when a subsequent small cell carcinoma of prostate occurs more than one year after acinar adenocarcinoma and/or an acinar subtype/variant.

OTHER-SITES RULES THAT CAN MATTER

M19 — Distinct histologies: Separate/non-contiguous tumors on different rows of the current Other Sites histology table are multiple primaries; timing is irrelevant.

SEER specifically confirms that separate acinar adenocarcinoma and small cell carcinoma diagnosed less than one year apart can still be separate primaries under M19 when M4 does not apply.

M20 — In situ then invasive: A separate invasive tumor occurring more than 60 days after an in situ tumor is abstracted as a new primary.

IMPORTANT: Multifocal acinar adenocarcinoma within the prostate does not create multiple primaries. Do not use PSA, Gleason/Grade Group, biomarkers, treatment response, or bilateral involvement alone to create a new primary.

SURGERY OF PRIMARY SITE — 2026

SURGERY CODE

—

No surgery selected.

CODING NOTE

Do not code orchiectomy in Surgery of Primary Site. For prostate primaries, orchiectomy is coded in Hematologic Transplant and Endocrine Procedures (NAACCR #3250).

PSA BY AGE — REFERENCE RANGES

AgeCommon age-specific upper reference
40–49≈ 2.5 ng/mL
50–59≈ 3.5 ng/mL
60–69≈ 4.5 ng/mL
70–79≈ 5.5 ng/mL
HOW TO USE THIS

These are age-specific reference limits, not a universal “average PSA.” PSA interpretation varies by age, race, prostate size, medications, infection/inflammation, laboratory reference range, and clinical context.

For cancer registry abstraction, code the qualifying pretreatment total serum PSA according to the SEER SSDI instructions. Do not substitute free PSA or precursor PSA.

SEER notes that normal PSA reference ranges vary by age and race and that the laboratory's own reference range should be used when available.

AMERICAN CANCER SOCIETY — UPDATED PROSTATE CANCER SCREENING GUIDELINES (2026)

The American Cancer Society has updated its guidelines to recommend routine prostate-specific antigen screening every two years for 50- to 69-year-old men at average risk.

The updated guideline recommends earlier and more frequent screening for men at higher risk and adds a more structured pathway for confirming and evaluating an elevated PSA.

SCREENING INTERVALS

Average risk: PSA-based screening every 2 years from ages 50–69.

High risk: Black men and non-Black men with a strong family history should undergo annual PSA-based screening from ages 45–69.

Family-history nuance: Non-Black men with one first-degree relative diagnosed at age 65 or older should be screened every 2 years from ages 45–69.

ELEVATED PSA FOLLOW-UP

Ages 45–69: PSA ≥ 3.0 ng/mL is considered elevated under the updated ACS screening pathway.

Ages 70–74: PSA ≥ 6.5 ng/mL is considered elevated.

Repeat an elevated PSA between 2 weeks and 3 months. If the elevation is confirmed, offer MRI and/or a validated biomarker to help guide the biopsy decision.

ODS / EDUCATION NOTE: These are screening recommendations, not cancer-registry reportability or staging rules. A PSA result alone does not establish a prostate cancer diagnosis.

EXTENT OF DISEASE (EOD)

EOD PRIMARY TUMOR

Code prostate extension using the 2026 SEER EOD prostate schema.

EOD REGIONAL NODES

Code regional pelvic nodal involvement separately from distant nodes.

EOD METS

Capture distant metastases including bone, distant nodes, and other organs as defined in the schema.

SEER SUMMARY STAGE 2018

SUMMARY STAGE CATEGORIES

Localized · Regional · Distant · Unknown. Apply the current prostate-specific Summary Stage 2018 rules rather than inferring directly from AJCC stage group.

IMPORTANT

AJCC, EOD, and Summary Stage are separate staging systems. Do not substitute one system's codes for another.

PROSTATE SSDI / STAGING FACTORS

PSA LAB VALUE

Pretreatment prostate-specific antigen value is needed for AJCC stage grouping.

GRADE CLINICAL

Grade Group 1–5 based on clinical-time-frame Gleason findings.

GRADE PATHOLOGICAL

Pathologic Grade Group when a qualifying pathologic specimen/time frame exists.

GRADE GROUP QUICK REFERENCE:
1 — Gleason ≤6 · 2 — Gleason 3+4=7 · 3 — Gleason 4+3=7 · 4 — Gleason 8 · 5 — Gleason 9–10

COMMON METASTATIC SITES — PROSTATE

Bone is a particularly important metastatic site in prostate cancer. Other recognized distant sites include liver, lung, adrenal gland, and distant lymph nodes.

COMMON

Bone

Bone metastases are common in prostate cancer and are specifically addressed in the prostate EOD Mets schema.

COMMON

Distant lymph nodes

Examples include aortic, common iliac, inguinal, and retroperitoneal nodes when classified as distant by schema.

COMMON

Liver

Recognized distant organ site.

COMMON

Lung

Recognized distant organ site.

COMMON

Adrenal gland

Listed by NCI among main sites of prostate cancer metastasis.

Registrar reminder: Common iliac nodes are distant for prostate EOD—not regional pelvic nodes. Code the exact documented nodal basin.

SOURCES

\n\n